Initially we found some evidence linking daytime sleepiness with lower odds of overall breast cancer mortality, and insomnia symptoms with lower odds of mortality in women with ER + /PR + /HER2- tumours (receiving no chemotherapy) and all patients receiving aromatase inhibitors. The gene discussed is CYP19A1; the disease is insomnia measurement.